International Isotopes raises $19.5 million:
This article was originally published in Clinica
International Isotopes has closed a two-stage private equity financing, raising $19.5 million. The company says that the proceeds, together with an expected increase in product revenues over the next six months, should provide it with a positive cash flow by the end of the year. International Isotopes, of Denton, Texas, has just begun commercial production of Iodine-125 brachytherapy seeds, used for the treatment of prostate cancer. The product is in clinical development for treating tumours in the breast, eye and oesophagus. The company plans to begin commercial shipments of six radioisotopes and radiochemicals during the third and fourth quarter.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.